Skip to main content

Experimental therapeutics and drug development

This section covers all aspects of preclinical investigations on therapeutic agents. It welcomes submissions concerning anti-cancer drug discovery and development, and targeted therapies.

Page 11 of 12

  1. Tamoxifen is used in hormone therapy for estrogen-receptor (ER)-positive breast cancer, but also has chemopreventative effects against ER-negative breast cancers. This study sought to investigate whether oral ...

    Authors: Xueying Sun, Ruohan Jiang, Aneta Przepiorski, Shiva Reddy, Kate P Palmano and Geoffrey W Krissansen

    Citation: BMC Cancer 2012 12:591

    Content type: Research article

    Published on:

  2. Curcumin inhibits growth of several cancer cell lines, and studies in this laboratory in bladder and pancreatic cancer cells show that curcumin downregulates specificity protein (Sp) transcription factors Sp1,...

    Authors: Shruti U Gandhy, KyoungHyun Kim, Lesley Larsen, Rhonda J Rosengren and Stephen Safe

    Citation: BMC Cancer 2012 12:564

    Content type: Research article

    Published on:

  3. Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. Current therapies are insufficient, making HCC an intractable disease. Our previous studies confirmed that inhibi...

    Authors: Wei Li, Dao-Ming Li, Kai Chen, Zheng Chen, Yang Zong, Hong Yin, Ze-Kuan Xu, Yi Zhu, Fei-Ran Gong and Min Tao

    Citation: BMC Cancer 2012 12:547

    Content type: Research article

    Published on:

  4. Treatment of solid tumors with vascular disrupting agent OXi4503 results in over 90% tumor destruction. However, a thin rim of viable cells persists in the tumor periphery following treatment, contributing to ...

    Authors: Linh Nguyen, Theodora Fifis, Caterina Malcontenti-Wilson, Lie Sam Chan, Patricia Nunes Luiza Costa, Mehrdad Nikfarjam, Vijayaragavan Muralidharan and Christopher Christophi

    Citation: BMC Cancer 2012 12:522

    Content type: Research article

    Published on:

  5. We have recently reported that the expression of peptidylarginine deiminase 2 (PADI2) is regulated by EGF in mammary cancer cells and appears to play a role in the proliferation of normal mammary epithelium; h...

    Authors: John L McElwee, Sunish Mohanan, Obi L Griffith, Heike C Breuer, Lynne J Anguish, Brian D Cherrington, Ashley M Palmer, Louise R Howe, Venkataraman Subramanian, Corey P Causey, Paul R Thompson, Joe W Gray and Scott A Coonrod

    Citation: BMC Cancer 2012 12:500

    Content type: Research article

    Published on:

  6. Despite strong efforts to improve clinical outcome of ovarian cancer patients by conventional and targeted immuno-based therapies, the prognosis of advanced ovarian cancer is still poor. Natural killer (NK) ce...

    Authors: Nina Gottschalk, Stephan Lang, Rainer Kimmig, Mahavir Singh and Sven Brandau

    Citation: BMC Cancer 2012 12:451

    Content type: Research article

    Published on:

  7. Chemotherapeutic bioassay for colorectal cancer (CRC) with a rat model bearing chemically-induced CRCs plays an important role in the development of new anti-tumor drugs and regimens. Although several protocol...

    Authors: Kazuto Yoshimi, Takao Hashimoto, Yusuke Niwa, Kazuya Hata, Tadao Serikawa, Takuji Tanaka and Takashi Kuramoto

    Citation: BMC Cancer 2012 12:448

    Content type: Research article

    Published on:

  8. DNA interstrand cross-links (ICLs) are critical lesions produced by several cancer chemotherapy agents including platinum drugs and nitrogen mustards. We have previously shown in haematological (multiple myelo...

    Authors: Victoria J Spanswick, Helen L Lowe, Claire Newton, John P Bingham, Alessia Bagnobianchi, Konstantinos Kiakos, Charles Craddock, Jonathan A Ledermann, Daniel Hochhauser and John A Hartley

    Citation: BMC Cancer 2012 12:436

    Content type: Research article

    Published on:

  9. Nucleoside analogs used in the chemotherapy of solid tumors, such as the capecitabine catabolite 5-deoxy-5-fluorouridine (5-DFUR) trigger a transcriptomic response that involves the aquaglyceroporin aquaporin 3...

    Authors: Laia Trigueros-Motos, Sandra Pérez-Torras, F Javier Casado, Míriam Molina-Arcas and Marçal Pastor-Anglada

    Citation: BMC Cancer 2012 12:434

    Content type: Research article

    Published on:

  10. The CD34+CD38- subset of AML cells is enriched for resistance to current chemotherapeutic agents and considered to contribute to disease progression and relapse in Acute Myeloid Leukaemia (AML) patients following...

    Authors: Mays Jawad, Ning Yu, Claire Seedhouse, Karuna Tandon, Nigel H Russell and Monica Pallis

    Citation: BMC Cancer 2012 12:431

    Content type: Research article

    Published on:

  11. Crosstalk between malignant hepatocytes and the surrounding peritumoral stroma is a key modulator of hepatocarcinogenesis and therapeutic resistance. To examine the chemotherapy resistance of these two cellula...

    Authors: Fatima Rangwala, Kevin P Williams, Ginger R Smith, Zainab Thomas, Jennifer L Allensworth, H Kim Lyerly, Anna Mae Diehl, Michael A Morse and Gayathri R Devi

    Citation: BMC Cancer 2012 12:402

    Content type: Research article

    Published on:

  12. Antiangiogenic agents that disrupt the vascular endothelial growth factor pathway have been demonstrated to normalize tumor vasculature and improve tumor oxygenation in some studies and to induce hypoxia in ot...

    Authors: Jon-Vidar Gaustad, Trude G Simonsen, Marit N Leinaas and Einar K Rofstad

    Citation: BMC Cancer 2012 12:388

    Content type: Research article

    Published on:

  13. Hepatocellular carcinoma (HCC) still represents an unmet medical need. Epigenetic inactivation of tumor suppressor genes like RASSF1A or APC by overexpression of DNA methyltransferases (DNMTs) has been shown t...

    Authors: Steffen Zopf, Matthias Ocker, Daniel Neureiter, Beate Alinger, Susanne Gahr, Markus F Neurath and Pietro Di Fazio

    Citation: BMC Cancer 2012 12:386

    Content type: Research article

    Published on:

  14. The investigational oral DNA vaccine VXM01 targets the vascular endothelial growth factor receptor 2 (VEGFR-2) and uses Salmonella typhi Ty21a as a vector. The immune reaction elicited by VXM01 is expected to dis...

    Authors: Andreas G Niethammer, Heinz Lubenau, Gerd Mikus, Philipp Knebel, Nicolas Hohmann, Christine Leowardi, Philipp Beckhove, Mustafa Akhisaroglu, Yingzi Ge, Marco Springer, Lars Grenacher, Markus W Buchler, Moritz Koch, Jürgen Weitz, Walter E Haefeli and Friedrich H Schmitz-Winnenthal

    Citation: BMC Cancer 2012 12:361

    Content type: Study protocol

    Published on:

  15. Limited penetration of anticancer drugs in solid tumours is a probable cause of drug resistance. Our previous results indicate that drug penetration depends on cellular packing density and adhesion between can...

    Authors: Rama H Grantab and Ian F Tannock

    Citation: BMC Cancer 2012 12:214

    Content type: Research article

    Published on:

  16. Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the chemotherapy efficacy against HCC is still unsatisfactory. The mammalian target of rapamycin (mTOR) has been emerged as an import...

    Authors: Cun Wang, Dongmei Gao, Kun Guo, Xiaonan Kang, Kai Jiang, Chun Sun, Yan Li, Lu Sun, Hong Shu, Guangzhi Jin, Haiyan Sun, Weizhong Wu and Yinkun Liu

    Citation: BMC Cancer 2012 12:166

    Content type: Research article

    Published on:

  17. The mammalian target of rapamycin (mTOR) is frequently activated in colon cancers due to mutations in the phosphatidylinositol 3-kinase (PI3K) pathway. Targeting mTOR with allosteric inhibitors of mTOR such as...

    Authors: Benjamin Blaser, Laurent Waselle, Anne Dormond-Meuwly, Marc Dufour, Didier Roulin, Nicolas Demartines and Olivier Dormond

    Citation: BMC Cancer 2012 12:86

    Content type: Research article

    Published on:

  18. Bevacizumab is a humanized monoclonal antibody to human vascular endothelial cell growth factor (VEGF) and has been used for many types of cancers such as colorectal cancer, non-small cell lung cancer, breast ...

    Authors: Yoriko Yamashita-Kashima, Kaori Fujimoto-Ouchi, Keigo Yorozu, Mitsue Kurasawa, Mieko Yanagisawa, Hideyuki Yasuno and Kazushige Mori

    Citation: BMC Cancer 2012 12:37

    Content type: Research article

    Published on:

  19. Ergosterol peroxide (EP) derived from edible mushroom has been shown to exert anti-tumor activity in several cancer cells. In the present study, anti-angiogenic activity of EP was investigated with the underly...

    Authors: Yun-Hee Rhee, Soo-Jin Jeong, Hyo-Jeong Lee, Hyo-Jung Lee, Wonil Koh, Ji Hoon Jung, Sun-Hee Kim and Kim Sung-Hoon

    Citation: BMC Cancer 2012 12:28

    Content type: Research article

    Published on:

  20. Stimulation of vascular endothelial growth factor (VEGF) has been observed following transarterial chemoembolization (TACE) in hepatocellular cancer (HCC) and may contribute to tumor regrowth. This pilot study...

    Authors: Carolyn D Britten, Antoinette S Gomes, Zev A Wainberg, David Elashoff, Rafael Amado, Yan Xin, Ronald W Busuttil, Dennis J Slamon and Richard S Finn

    Citation: BMC Cancer 2012 12:16

    Content type: Research article

    Published on:

  21. The multicellular tumor spheroid (MCTS) is an in vitro model associating malignant-cell microenvironment and 3D organization as currently observed in avascular tumors.

    Authors: Isabelle Dufau, Céline Frongia, Flavie Sicard, Laure Dedieu, Pierre Cordelier, Frédéric Ausseil, Bernard Ducommun and Annie Valette

    Citation: BMC Cancer 2012 12:15

    Content type: Research article

    Published on:

  22. Invasive micropapillary carcinoma (IMPC) of the breast is a distinct and aggressive variant of luminal type B breast cancer that does not respond to neoadjuvant chemotherapy. It is characterized by small pseud...

    Authors: Sophie Doublier, Dimas C Belisario, Manuela Polimeni, Laura Annaratone, Chiara Riganti, Elena Allia, Dario Ghigo, Amalia Bosia and Anna Sapino

    Citation: BMC Cancer 2012 12:4

    Content type: Research article

    Published on:

  23. Statins have long been used as anti-hypercholesterolemia drugs, but numerous lines of evidence suggest that they may also bear anti-tumour potential. We have recently demonstrated that it was possible to isola...

    Authors: Julie Follet, Lionel Rémy, Vincent Hesry, Brigitte Simon, Danièle Gillet, Pierrick Auvray, Laurent Corcos and Catherine Le Jossic-Corcos

    Citation: BMC Cancer 2011 11:491

    Content type: Research article

    Published on:

  24. Worldwide, cervical cancer is the second most common causes of cancer in women and represents an important mortality rate. Cisplatin (CIS) is a very important antitumoral agent and can lead tumor cells toward ...

    Authors: Georgina Hernandez-Flores, Pablo C Ortiz-Lazareno, Jose Manuel Lerma-Diaz, Jorge R Dominguez-Rodriguez, Luis F Jave-Suarez, Adriana del C Aguilar-Lemarroy, Ruth de Celis-Carrillo, Susana del Toro-Arreola, Yessica C Castellanos-Esparza and Alejandro Bravo-Cuellar

    Citation: BMC Cancer 2011 11:483

    Content type: Research article

    Published on:

  25. N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) is a synthetic retinoid with potent pro-apoptotic activity against several types of cancer, but little is known regarding mechanisms leading to chemoresistance....

    Authors: Aintzane Apraiz, Jolanta K Idkowiak-Baldys, María Dolores Boyano, Gorka Pérez-Yarza, Yusuf A Hannun and Aintzane Asumendi

    Citation: BMC Cancer 2011 11:477

    Content type: Research article

    Published on:

  26. HER2/neu is an oncogene that facilitates neoplastic transformation due to its ability to transduce growth signals in a ligand-independent manner, is over-expressed in 20-30% of human breast cancers correlating w...

    Authors: Tobias Hahn, Deborah J Bradley-Dunlop, Laurence H Hurley, Daniel Von-Hoff, Stephen Gately, Disis L Mary, Hailing Lu, Manuel L Penichet, David G Besselsen, Brook B Cole, Tanisha Meeuwsen, Edwin Walker and Emmanuel T Akporiaye

    Citation: BMC Cancer 2011 11:471

    Content type: Research article

    Published on:

  27. Tumor Necrosis Factor-α Related Apoptosis Inducing Ligand (TRAIL) and agonistic antibodies to death receptor 4 and 5 are promising candidates for cancer therapy due to their ability to induce apoptosis selective...

    Authors: David J Taylor, Christine E Parsons, Haiyong Han, Arul Jayaraman and Kaushal Rege

    Citation: BMC Cancer 2011 11:470

    Content type: Research article

    Published on:

  28. The molecular chaperone, heat shock protein 90 (Hsp90) has been shown to be overexpressed in a number of cancers, including prostate cancer, making it an important target for drug discovery. Unfortunately, res...

    Authors: Jeffery D Eskew, Takrima Sadikot, Pedro Morales, Alicia Duren, Irene Dunwiddie, Megan Swink, Xiaoying Zhang, Stacey Hembruff, Alison Donnelly, Roger A Rajewski, Brian SJ Blagg, Jacob R Manjarrez, Robert L Matts, Jeffrey M Holzbeierlein and George A Vielhauer

    Citation: BMC Cancer 2011 11:468

    Content type: Research article

    Published on:

  29. Primary effusion lymphoma (PEL) is a rare KSHV/HHV8-associated high-grade non-Hodgkin's lymphoma (NHL) of B-cell origin, characterized by serous effusions in body cavities. Most patients are HIV-infected men w...

    Authors: Rita Ötvös, Henriette Skribek, Lorand L Kis, Annunziata Gloghini, Laszlo Markasz, Emilie Flaberg, Staffan Eksborg, Jozsef Konya, Lajos Gergely, Antonino Carbone and Laszlo Szekely

    Citation: BMC Cancer 2011 11:441

    Content type: Research article

    Published on:

  30. HER2-positive breast cancers exhibit high rates of innate and acquired resistance to trastuzumab (TZ), a HER2-directed antibody used as a first line treatment for this disease. TZ resistance may in part be med...

    Authors: Wieslawa H Dragowska, Sherry A Weppler, Mohammed A Qadir, Ling Yan Wong, Yannick Franssen, Jennifer HE Baker, Anita I Kapanen, Guido JJ Kierkels, Dana Masin, Andrew I Minchinton, Karen A Gelmon and Marcel B Bally

    Citation: BMC Cancer 2011 11:420

    Content type: Research article

    Published on:

  31. Epidermal growth factor receptor (EGFR) and its downstream factors KRAS and BRAF are mutated in several types of cancer, affecting the clinical response to EGFR inhibitors. Mutations in the EGFR kinase domain pre...

    Authors: Emma Borràs, Ismael Jurado, Imma Hernan, María José Gamundi, Miguel Dias, Isabel Martí, Begoña Mañé, Àngels Arcusa, José AG Agúndez, Miguel Blanca and Miguel Carballo

    Citation: BMC Cancer 2011 11:406

    Content type: Research article

    Published on:

  32. Multiple myeloma (MM) is a fatal malignancy ranking second in prevalence among hematological tumors. Continuous efforts are being made to develop innovative and more effective treatments. The preclinical evalu...

    Authors: Leonardo Mirandola, Yuefei Yu, Marjorie R Jenkins, Raffaella Chiaramonte, Everardo Cobos, Constance M John and Maurizio Chiriva-Internati

    Citation: BMC Cancer 2011 11:394

    Content type: Research article

    Published on:

  33. Single drug use has not achieved satisfactory results in the treatment of prostate cancer, despite application of increasingly widespread targeted therapeutics. In the present study, the combined impact of the...

    Authors: Steffen Wedel, Lukasz Hudak, Jens-Michael Seibel, Jasmina Makarević, Eva Juengel, Igor Tsaur, Ana Waaga-Gasser, Axel Haferkamp and Roman A Blaheta

    Citation: BMC Cancer 2011 11:375

    Content type: Research article

    Published on:

  34. Late stage Ovarian Cancer is essentially incurable primarily due to late diagnosis and its inherent heterogeneity. Single agent treatments are inadequate and generally lead to severe side effects at therapeuti...

    Authors: Preetinder P Singh, Swapna Joshi, Pamela J Russell, Sham Nair and Aparajita Khatri

    Citation: BMC Cancer 2011 11:368

    Content type: Research article

    Published on:

  35. The primary goal of current chemotherapy in hepatoblastoma (HB) is reduction of tumour volume and vitality to enable complete surgical resection and reduce risk of recurrence or metastatic disease. Drug resist...

    Authors: Justus Lieber, Carmen Eicher, Julia Wenz, Bettina Kirchner, Steven W Warmann, Jörg Fuchs and Sorin Armeanu-Ebinger

    Citation: BMC Cancer 2011 11:362

    Content type: Research article

    Published on:

  36. Transferrin receptor (TfR) is a cell membrane-associated glycoprotein involved in the cellular uptake of iron and the regulation of cell growth. Recent studies have shown the elevated expression levels of TfR ...

    Authors: Megumi Kawamoto, Tomohisa Horibe, Masayuki Kohno and Koji Kawakami

    Citation: BMC Cancer 2011 11:359

    Content type: Research article

    Published on:

  37. Nucleolin expressed at the cell surface is a binding protein for a variety of ligands implicated in tumorigenesis and angiogenesis. By using a specific antagonist that binds the C-terminal RGG domain of nucleo...

    Authors: Bernard Krust, Diala El Khoury, Isabelle Nondier, Calaiselvy Soundaramourty and Ara G Hovanessian

    Citation: BMC Cancer 2011 11:333

    Content type: Research article

    Published on:

  38. Polysaccharides extracted from the Phellinus linteus (PL) mushroom are known to possess anti-tumor effects. However, the molecular mechanisms responsible for the anti-tumor properties of PL remain to be explored....

    Authors: Kyoung-Sub Song, Ge Li, Jong-Seok Kim, Kaipeng Jing, Tae-Dong Kim, Jin-Pyo Kim, Seung-Bo Seo, Jae-Kuk Yoo, Hae-Duck Park, Byung-Doo Hwang, Kyu Lim and Wan-Hee Yoon

    Citation: BMC Cancer 2011 11:307

    Content type: Research article

    Published on:

  39. Targeting of the renin angiotensin system (RAS) reduces tumour growth in experimental models of cancer. We aimed to establish if combined targeting of the 'classical' and 'alternative' arms of the RAS could re...

    Authors: Eleanor I Ager, Shu Wen Wen, Joyna Chan, Way W Chong, Jaclyn H Neo and Christopher Christophi

    Citation: BMC Cancer 2011 11:274

    Content type: Research article

    Published on:

  40. Flaxseed (FS) is a dietary supplement known for its antioxidant and anti-inflammatory properties. Radiation exposure of lung tissues occurs either when given therapeutically to treat intrathoracic malignancies...

    Authors: Melpo Christofidou-Solomidou, Sonia Tyagi, Kay-See Tan, Sarah Hagan, Ralph Pietrofesa, Floyd Dukes, Evguenia Arguiri, Daniel F Heitjan, Charalambos C Solomides and Keith A Cengel

    Citation: BMC Cancer 2011 11:269

    Content type: Research article

    Published on:

  41. Cucurbitacin-I (JSI-124) is potent inhibitor of JAK/STAT3 signaling pathway and has anti-tumor activity in a variety of cancer including B cell leukemia. However, other molecular targets of JSI-124 beyond the ...

    Authors: Ganchimeg Ishdorj, James B Johnston and Spencer B Gibson

    Citation: BMC Cancer 2011 11:268

    Content type: Research article

    Published on:

  42. Cladribine or 2-chlorodeoxyadenosine (2-CDA) is a well-known purine nucleoside analog with particular activity against lymphoproliferative disorders, such as hairy cell leukemia (HCL). Its benefits in multiple...

    Authors: Jian Ma, Shuiliang Wang, Ming Zhao, Xin-Sheng Deng, Choon-Kee Lee, Xiao-Dan Yu and Bolin Liu

    Citation: BMC Cancer 2011 11:255

    Content type: Research article

    Published on:

  43. Aurora kinases play an essential role in orchestrating chromosome alignment, segregation and cytokinesis during mitotic progression, with both aurora-A and B frequently over-expressed in a variety of human mal...

    Authors: Martin Grundy, Claire Seedhouse, Nigel H Russell and Monica Pallis

    Citation: BMC Cancer 2011 11:254

    Content type: Research article

    Published on:

  44. Aromatase inhibitors (AI) that inhibit breast cancer cell growth by blocking estrogen synthesis have become the treatment of choice for post-menopausal women with estrogen receptor positive (ER+) breast cancer. H...

    Authors: Tesfom Abrhale, Angela Brodie, Gauri Sabnis, Luciana Macedo, Changsheng Tian, Binbin Yue and Ginette Serrero

    Citation: BMC Cancer 2011 11:231

    Content type: Research article

    Published on:

  45. Reovirus type 3 Dearing (T3D) has demonstrated oncolytic activity in vitro, in in vivo murine models and in early clinical trials. However the true potential of oncolytic viruses may only be realized fully in com...

    Authors: Lucy Heinemann, Guy R Simpson, Angela Boxall, Timothy Kottke, Kate L Relph, Richard Vile, Alan Melcher, Robin Prestwich, Kevin J Harrington, Richard Morgan and Hardev S Pandha

    Citation: BMC Cancer 2011 11:221

    Content type: Research article

    Published on:

  46. Hepatocellular carcinoma (HCC) usually has a dismal prognosis because of its limited response to current pharmacotherapy and high metastatic rate. Sulfated oligosaccharide has been confirmed as having potent a...

    Authors: Chun-Li Xiao, Zhong-Hua Tao, Lin Guo, Wei-Wei Li, Jin-Liang Wan, Hui-Chuan Sun, Lu Wang, Zhao-You Tang, Jia Fan and Wei-Zhong Wu

    Citation: BMC Cancer 2011 11:150

    Content type: Research article

    Published on:

  47. Curcumin is a naturally occurring phenolic compound shown to have a wide variety of antitumor activities; however, it does not attain sufficient blood levels to do so when ingested. Using structure-based desig...

    Authors: Stacey L Fossey, Misty D Bear, Jiayuh Lin, Chenglong Li, Eric B Schwartz, Pui-Kai Li, James R Fuchs, Joelle Fenger, William C Kisseberth and Cheryl A London

    Citation: BMC Cancer 2011 11:112

    Content type: Research article

    Published on: